PURPOSE: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. PATIENTS AND METHODS: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. RESULTS: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. CONCLUSION: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.
PURPOSE: The present study analyzed the polymorphisms of apoptosis-related genes and their impact on the response to chemotherapy and survival of patients with colorectal cancer. PATIENTS AND METHODS: A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study. The single nucleotide polymorphisms of 15 apoptosis-related genes (TP53, BCL2L, TNFRSF10B, AKT1, PTGS2/COX2, BID, RIPK1, FAS, FASL, caspase 3, and caspase 6-10) were determined using a PCR-RFLP assay. RESULTS: No significant association between the polymorphisms and the response was found for any of the genes analyzed. However, the T/T genotype of PTGS2 8473T>C (rs5275) was significantly correlated with a better progression-free survival (PFS) and overall survival (OS) when compared to the combined T/C and C/C genotype (Hazard ratio [HR] = 0.47; P value = 0.046 and HR = 0.16; P = 0.013, respectively) in a multivariate analysis adjusted for age, sex, performance status, disease status and curative resection. No association was noted between the other polymorphisms and survival. CONCLUSION: The PTGS2 8473T>C polymorphism was found to be correlated with PFS and OS in patients with advanced colorectal cancer treated with XELOX chemotherapy.
Authors: Sarah M Rausch; Brian D Gonzalez; Matthew M Clark; Christi Patten; Sara Felten; Heshan Liu; Yafei Li; Jeff Sloan; Ping Yang Journal: Lung Cancer Date: 2012-03-29 Impact factor: 5.705
Authors: Jun Young Choi; Jong Gwang Kim; You Jin Lee; Yee Soo Chae; Sang Kyun Sohn; Joon Ho Moon; Byung Woog Kang; Min Kyu Jung; Seong Woo Jeon; Jun Seok Park; Gyu Seog Choi Journal: Cancer Res Treat Date: 2012-03-31 Impact factor: 4.679
Authors: Sevtap Savas; Jingxiong Xu; Salem Werdyani; Konstantin Shestopaloff; Elizabeth Dicks; Jane Green; Patrick Parfrey; Roger Green; Wei Xu Journal: Biomed Res Int Date: 2015-05-12 Impact factor: 3.411
Authors: Arancha Cebrián; Teresa Gómez Del Pulgar; María José Méndez-Vidal; María Luisa Gonzálvez; Nuria Lainez; Daniel Castellano; Iciar García-Carbonero; Emilio Esteban; Maria Isabel Sáez; Rosa Villatoro; Cristina Suárez; Alfredo Carrato; Javier Munárriz-Ferrándiz; Laura Basterrechea; Mirta García-Alonso; José Luis González-Larriba; Begoña Perez-Valderrama; Josefina Cruz-Jurado; Aránzazu González Del Alba; Fernando Moreno; Gaspar Reynés; María Rodríguez-Remírez; Valentina Boni; Ignacio Mahillo-Fernández; Yolanda Martin; Andrea Viqueira; Jesús García-Foncillas Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379